SCHEMBL3310704

SCHEMBL3310704

CCOC(=O)[C@H]1CCC(=O)N1Cc1cc(OC)c(C(C)(C)C)cc1Br

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.47
CA2 P00918 6/20 0.47
CA9 Q16790 5/20 0.47
CA12 O43570 3/20 0.47
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.41
TSHR P16473 3/20 0.41
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ADRA1A P35348 2/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
ADRA1D P25100 1/20 0.38
ADRA1B P35368 1/20 0.38
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2356493 1.00 CA1 (0.47) CA1CA2CA9CA12ALDH1A1
SCHEMBL2364234 0.80 ADRA1A (0.37) ALDH1A1KDM4ETSHRKMT2AMEN1
SCHEMBL2364233 0.80 ADRA1A (0.37) ALDH1A1KDM4ETSHRKMT2AMEN1
SCHEMBL7982379 0.76 ALDH1A1 (0.48) CA1CA2CA9CA12ALDH1A1
SCHEMBL7982377 0.76 ALDH1A1 (0.48) CA1CA2CA9CA12ALDH1A1
SCHEMBL3314174 0.76 HCRTR2 (0.35) CA1CA2CA9CA12
SCHEMBL3311920 0.75 GYS1 (0.39) ALDH1A1KDM4EADRA1AADRA1DADRA1B
SCHEMBL3311912 0.75 GYS1 (0.39) ALDH1A1KDM4EADRA1AADRA1DADRA1B
SCHEMBL7354279 0.74 ALDH1A1 (0.47) CA1CA2CA9CA12ALDH1A1
SCHEMBL7982380 0.74 ALDH1A1 (0.47) CA1CA2CA9CA12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CA1 4874/4885CA2 4835/4885CA9 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.